Watson: FDA approves generic contraceptive to be launched as Quasense

By Lisa Kerner

Charlotte, N.C., Sept. 7 - The Food and Drug Administration granted final approval to Watson Pharmaceuticals, Inc.'s abbreviated New Drug Application for levonorgestrel/ethinyl estradiol tablets USP, 0.15 mg / 0.03 mg.

The specialty pharmaceutical company's product is the generic equivalent to Duramed Pharmaceuticals' Seasonale extended-cycle oral contraceptive for prevention of pregnancy, which had sales of $110 million for the 12 months through June.

Watson, located in Corona, Calif., said it intends to launch its product immediately under the trade name Quasense.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.